TICKERNERD
Menu
RVTYRVTYHealthcare · Diagnostics & Research

RVTY Stock Forecast: Revvity, Inc. Price Predictions for 2026-2027

Last close, 4 Sept 2026
$130
−0.31% on the day

The 18 Wall Street analysts covering Revvity, Inc. hold a median 12-month price target of $124 — -5.2% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 94 of 100 as at 5 Sept 2026 — among the strongest tenth. The factors read stronger than the Street's target implies. That gap is the story on this page.

Market cap
$14.5B
Ticker Nerd rank
94 / 100
Median analyst target
$124
Analysts covering
18
Revenue$729.7M+1.3% y/y
Operating income$87.9M
Net income$51.8M
Free cash flow$180.9M
Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
+1.1%
1M
+16.9%
YTD
+34.9%
1Y
+52.4%
From 52W high
−0.5%
From 52W low
+58.4%
$82
$131
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

RVTY stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Revvity, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 5 Sept 2026
94 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Value
91
Issuance
90
Revisions
85
Volatility
84
Momentum
83
Accruals
72
Quality
58
Growth
56
Size
12

Value (91): The shares cost little relative to the profits and assets behind them — which can mean the market is too gloomy, or that the business really is in trouble.

Growth (56): Sales and profits are flat, shrinking, or growing more slowly than they were.

Size (12): Larger than most of the companies we track — more scrutinised, less often mispriced.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

RVTY stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on RVTY, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$80$100$120$140$160Oct 25Jan 26Apr 26Jul 26RVTYHigh $165Median $124Low $100

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says18 analysts
6 Buy12 Hold0 Sell
Low $100Median $124High $165

The green dot is the last close — the median target sits −5.2% from it.

Recent analyst actionsNewest first

Of the 20 most recent actions, 3 moved their price target up and 0 moved it down.

DateFirmActionRatingTarget
4 Sept 2026KeybancMaintainsOverweight$125 → $165
1 Sept 2026RBC CapitalInitiatesSector Perform$135
5 Aug 2026Evercore ISI GroupMaintainsOutperform$125 → $126
5 Aug 2026Evercore ISI GroupMaintainsOutperform—
6 July 2026Evercore ISI GroupMaintainsOutperform$110 → $125
6 July 2026Evercore ISI GroupMaintainsOutperform—
26 June 2026BernsteinReinstatesMarket Perform$115
2 June 2026Wolfe ResearchAssumesPeer Perform—
7 May 2026BarclaysMaintainsEqual-Weight—
6 May 2026JP MorganMaintainsNeutral—
6 May 2026StifelMaintainsHold—
6 May 2026TD CowenMaintainsBuy—
4 May 2026BairdMaintainsOutperform—
14 Apr 2026BarclaysDowngradeEqual-Weight—
14 Apr 2026Goldman SachsMaintainsNeutral—
31 Mar 2026JP MorganMaintainsNeutral—
3 Feb 2026BarclaysMaintainsOverweight—
3 Feb 2026Evercore ISI GroupMaintainsOutperform—
3 Feb 2026JefferiesMaintainsHold—
3 Feb 2026JP MorganMaintainsNeutral—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. RVTY appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

Performance

RVTY vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 4 Sept 2026, Revvity, Inc. returned +52.4% against +20.0% for the S&P 500, dividends included.

RVTY vs S&P 500, last 12 monthsTotal return, rebased to 100
90100110120130140150160Oct 25Jan 26Apr 26Jul 26RVTYS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

RVTY analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
EPS revision, 90 days
+2.0%
Analysts raising
10
Analysts cutting
0
Fundamentals

Revvity, Inc. (RVTY) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
62.6×

Cheaper than 11% of US stocks

Price / sales
5.0×

Cheaper than 25% of US stocks

Price / book
2.0×

Cheaper than 47% of US stocks

EV / EBITDA
19.2×

Cheaper than 16% of US stocks

Growth & margins
Revenue growth (YoY)
1.3%

Higher than 30% of US stocks

Earnings growth (YoY)
−3.9%

Higher than 32% of US stocks

Gross margin
57.1%

Higher than 70% of US stocks

Operating margin
17.1%

Higher than 75% of US stocks

Net margin
8.2%

Higher than 66% of US stocks

Returns & dividend
Return on equity
3.2%

Higher than 50% of US stocks

Return on assets
2.4%

Higher than 61% of US stocks

Dividend yield
0.2%

Higher than 4% of US dividend payers

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Key statistics

Revvity, Inc. (RVTY) statistics: revenue, profit & scale

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • Revvity, Inc. has a market value of $14.5B and an enterprise value of $16.8B.

  • Revenue in the twelve months to 30 June 2026: $2.9B. The latest quarter grew 1.3% year on year.

  • Net income over the same four quarters: $237.6M, a 8.2% net margin.

  • Diluted earnings per share, trailing twelve months: $2.09.

  • Free cash flow in the twelve months to 30 June 2026: $558.1M, after $69.5M of capital spending.

  • Revvity, Inc. spent $475.8M on share buybacks and $31.7M on dividends in the twelve months to 30 June 2026.

  • Shares outstanding: 111.6M.

  • Trailing P/E: 62.6×; forward P/E: 22.1× — the forward figure prices analyst consensus estimates, not reported earnings.

  • Forward dividend yield: 0.22%, paying out 13% of earnings.

  • Revvity, Inc. employs 11,000 people — $265K of revenue per employee.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 6 Sept 2026

Data provided by Twelve Data

Peers

RVTY vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelDiagnostics & Research
CompanyMarket capTKN rank
RVTYRevvity, Inc.$14.5B
94
CRLCharles River Laboratories International, Inc.$14.2B
84
ICLRIcon PLC$12.6B
70
MEDPMedpace Holdings, Inc.$16.9B
97
GHGuardant Health, Inc.$20.9B
44
QGENQiagen NV$9.0B
63
DGXQuest Diagnostics, Inc.$26.4B
94

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own Revvity, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest RVTY news & analysis

Is Revvity Stock a Buy as Growth Improves but Valuation Stays Rich?

Zacks Investment Research · 4 Sept 2026neutral

Revvity has raised its 2026 outlook while showing Diagnostics growth and stronger cash flow, which brightens its setup. However, the company continues to carry a premium valuation alongside software-related risks, leading the article to advise a selective approach.

Why it matters — RVTY watchers would care because the improved outlook and cash flow are tempered by valuation and software risks, leaving a balanced picture for evaluating the stock's prospects.

What Makes Revvity (RVTY) a New Buy Stock

Zacks Investment Research · 1 Sept 2026positive

Revvity (RVTY) was upgraded by Zacks Investment Research to a Zacks Rank #2 (Buy), reflecting growing optimism about its earnings prospects. The upgrade suggests the stock might move higher on expectations of improved earnings.

Why it matters — A rank upgrade signals improved earnings expectations, which RVTY watchers would see as a positive development for the company's outlook.

Is the Options Market Predicting a Spike in Revvity Stock?

Zacks Investment Research · 24 Aug 2026neutral

Zacks Investment Research reports that recent movements in the options market warrant close attention to Revvity (RVTY) stock. The article highlights the activity in RVTY options as a point of interest for investors.

Why it matters — Revvity watchers would care because unusual options activity can signal how investors are positioning around the stock.

Revvity Launches SuperFlex Prenatal Screening System for Smaller Labs

Zacks Investment Research · 13 Aug 2026positive

Revvity launched SuperFlex, a compact automated prenatal screening system aimed at enabling rapid in-house testing for smaller labs and clinics. The system is designed to expand access to in-house prenatal screening in these settings.

Why it matters — RVTY watchers would care because the new product extends Revvity's prenatal screening offering to smaller labs and clinics, potentially broadening its customer base in that segment.

Revvity to Present at Upcoming Investor Conferences

Business Wire · 11 Aug 2026neutral

Revvity, Inc. announced it will present at three upcoming investor conferences: the Wells Fargo 21st Annual Healthcare Conference on September 9, 2026, featuring CEO Prahlad Singh; the Morgan Stanley 24th Annual Global Healthcare Conference on September 14, 2026, featuring CFO Max Krakowiak; and Baird's 2026 Global Healthcare Conference.

Why it matters — Revvity watchers may be interested as the company's CEO and CFO will provide updates and interact with investors at these major healthcare industry conferences.

FAQ

Frequently asked questions about RVTY stock

What is the RVTY stock price forecast for 2026-2027?

The 18 Wall Street analysts covering Revvity, Inc. have a median 12-month price target of $124, with estimates ranging from $100 to $165. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is RVTY stock a buy right now?

Of the 18 analysts covering Revvity, Inc., 6 rate it a Buy, 12 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Revvity, Inc. 94 out of 100 across roughly 4,600 US stocks as at 5 Sept 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank RVTY?

As at 5 Sept 2026, Revvity, Inc. ranks 94 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Value (91 of 100).

Will RVTY stock go up?

No one can know that. What the data says: the median 12-month target from 18 analysts implies -5.2% from the last close, and Ticker Nerd's factor model ranks Revvity, Inc. 94 out of 100 as at 5 Sept 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the RVTY stock forecast for 2030?

No analyst covering Revvity, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for RVTY are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $100 to $165 over the next 12 months.

How has RVTY stock performed over the past year?

Revvity, Inc. returned +52.4% over the 12 months to 4 Sept 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Revvity, Inc. do?

Revvity Inc. is a global life sciences and diagnostics company that provides health science solutions, technologies, and services for research, development, and clinical testing.

What is the latest news on RVTY?

The most recent item we track (Zacks Investment Research, 4 Sept 2026): "Is Revvity Stock a Buy as Growth Improves but Valuation Stays Rich?". Revvity has raised its 2026 outlook while showing Diagnostics growth and stronger cash flow, which brightens its setup. However, the company continues to carry a premium valuation alongside software-related risks, leading the article to advise a selective approach.

Company

About Revvity, Inc.

Revvity Inc. is a global life sciences and diagnostics company that provides health science solutions, technologies, and services for research, development, and clinical testing. Revvity’s current business is organized around two main segments: Life Sciences, which supplies reagents, instruments, and software to support biopharma and academic research; and Diagnostics, which offers assay platforms, instruments, and software for reproductive health, immunodiagnostics, newborn screening, applied genomics, and infectious disease testing. The company also focuses on translational multi-omics, biomarker identification, imaging, screening, detection, and informatics, helping customers move biological data through connected laboratory workflows. Revvity serves pharmaceutical and biotechnology companies, diagnostic laboratories, academic institutions, and government organizations across global markets. Headquartered in Waltham, Massachusetts, Revvity plays an important role in enabling scientific discovery and supporting clinical decision-making across the healthcare and research ecosystem.

CEO Dr. Prahlad R. Singh Ph.D. · 11,000 employees · United States · https://www.revvity.com